Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure

Glaukos Corporation (GKOS) is down 8.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The day’s drop looks less like a single fundamental shock and more like a pullback after a sharp multi-week rally following upbeat quarterly results and higher full-year sales guidance. Recent SEC filings showing stock sales tied to pre-arranged trading plans may also have contributed to short-term selling pressure.

Details:

Glaukos recently reported first-quarter 2026 results and discussed continued momentum in its glaucoma franchise, which had helped lift the stock in prior sessions.

Management raised (or reiterated at a higher level) its 2026 net sales outlook in that update, leaving shares priced for strong execution and making them vulnerable to profit-taking.

An SEC Form 4 filed in early May disclosed the company’s CFO exercised options and sold 10,000 shares on April 30, 2026, with the filing noting the transaction was executed under a Rule 10b5-1 trading plan.

Market commentary around the move has also emphasized valuation/positioning rather than a fresh product or regulatory headline, which can amplify downside volatility on red days.

Sources:

Glaukos Investor Relations, SEC EDGAR, AAII

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$GKOS Insider Trading Activity

$GKOS insiders have traded $GKOS stock on the open market 33 times in the past 6 months. Of those trades, 0 have been purchases and 33 have been sales.

Here’s a breakdown of recent trading of $GKOS stock by insiders over the last 6 months:

THOMAS WILLIAM BURNS (CHAIRMAN & CEO) has made 0 purchases and 2 sales selling 275,000 shares for an estimated $31,625,000.
JOSEPH E GILLIAM (PRESIDENT & COO) has made 0 purchases and 6 sales selling 34,573 shares for an estimated $4,711,062.
ALEX R. THURMAN (SVP & CHIEF FINANCIAL OFFICER) has made 0 purchases and 5 sales selling 14,972 shares for an estimated $1,922,434.
MARC STAPLEY has made 0 purchases and 5 sales selling 15,000 shares for an estimated $1,915,576.
GILBERT H KLIMAN has made 0 purchases and 3 sales selling 15,000 shares for an estimated $1,915,150.
AIMEE S WEISNER has made 0 purchases and 4 sales selling 15,000 shares for an estimated $1,760,761.
TOMAS NAVRATIL (CHIEF DEVELOPMENT OFFICER) has made 0 purchases and 7 sales selling 3,124 shares for an estimated $347,253.
LEANA WEN sold 1,700 shares for an estimated $243,695

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$GKOS Hedge Fund Activity

We have seen 155 institutional investors add shares of $GKOS stock to their portfolio, and 208 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JANUS HENDERSON GROUP PLC added 1,953,578 shares (+183.4%) to their portfolio in Q4 2025, for an estimated $220,578,491
CITADEL ADVISORS LLC added 1,419,970 shares (+5267.7%) to their portfolio in Q1 2026, for an estimated $152,873,970
MACQUARIE GROUP LTD removed 600,228 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $67,771,743
AMERIPRISE FINANCIAL INC removed 493,520 shares (-23.5%) from their portfolio in Q1 2026, for an estimated $53,132,363
DRIEHAUS CAPITAL MANAGEMENT LLC added 487,912 shares (+inf%) to their portfolio in Q1 2026, for an estimated $52,528,605
UBS GROUP AG removed 487,542 shares (-55.8%) from their portfolio in Q1 2026, for an estimated $52,488,771
JENNISON ASSOCIATES LLC added 487,020 shares (+inf%) to their portfolio in Q1 2026, for an estimated $52,432,573

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$GKOS Government Contracts

We have seen $265,092 of award payments to $GKOS over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

TRAVOPROST 75MCG: $169,104
NSC SURGICAL IMPLANT LEFT EYE IDOSE ISENT: $21,340
PROSTHETICS. SURGICAL IMPLANT RIGHT EYE IDOSE ISENT: $21,340
PROSTHETICS. NSC SURGICAL IMPLANT LEFT EYE IDOSE ISENT: $21,340
IDOSE TRAVOPROST 75MCG IMPLANT: $21,310

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$GKOS Analyst Ratings

Wall Street analysts have issued reports on $GKOS in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 05/21/2026
Truist Securities issued a "Buy" rating on 12/18/2025
Needham issued a "Buy" rating on 12/09/2025

To track analyst ratings and price targets for $GKOS, check out Quiver Quantitative's $GKOS forecast page.

$GKOS Price Targets

Multiple analysts have issued price targets for $GKOS recently. We have seen 9 analysts offer price targets for $GKOS in the last 6 months, with a median target of $145.0.

Here are some recent targets:

Ryan Zimmerman from BTIG set a target price of $162.0 on 05/21/2026
David Saxon from Needham set a target price of $136.0 on 04/30/2026
Larry Biegelsen from Wells Fargo set a target price of $138.0 on 04/30/2026
Joanne Wuensch from Citigroup set a target price of $140.0 on 04/30/2026
Allen Gong from JP Morgan set a target price of $140.0 on 04/30/2026
Thomas Stephan from Stifel set a target price of $160.0 on 01/22/2026
George Sellers from Stephens & Co. set a target price of $145.0 on 01/02/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.